Posted by Denise1904 on September 8, 2004, at 12:18:30
In reply to Neurocognitive effects of RU-486 for Bipolar dis, posted by jrbecker on August 2, 2004, at 11:58:32
Hi,
I contacted Professor Young at Newcastle with a view to participating in anymore trials and he sent me details of the study. The same ones that have been posted on this board.
Anyway, Can somebody please clarify the below paragraph? On one hand it says that depression score ratings had significantly improved after 14 days and that there were no improvements with placebo after 14 days but then it says that Direct comparison of the advantage of mifepristone over placebo at this time point (+14 days), however, failed to reach statistical significance? How can this be, it seems a bit contradictory?
Thanks.... Denise
At +14 days, following treatment with mifepristone, depression rating scores from the HDRS17 and MADRS had significantly improved from baseline levels (see Table 2). No significant change was observed at any time point following placebo. Direct comparison of the advantage of mifepristone over placebo at this time point (+14 days), however, failed to reach statistical significance for either HDRS17 scores (mean difference=2.32, 95% CI=-2.08 to 6.71; t=1.107, df=18, p=0.283) or MADRS scores (mean difference=2.26, 95%CI=-3.36 to 7.89; t=0.845, df=18, p=0.409).
poster:Denise1904
thread:371835
URL: http://www.dr-bob.org/babble/20040904/msgs/388038.html